Base de dados : MEDLINE
Pesquisa : D12.644.276.374.410 [Categoria DeCS]
Referências encontradas : 2325 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 233 ir para página                         

  1 / 2325 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27888331
[Au] Autor:Devi KS; Anandasabapathy N
[Ad] Endereço:Department of Dermatology/Harvard Skin Disease Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
[Ti] Título:The origin of DCs and capacity for immunologic tolerance in central and peripheral tissues.
[So] Source:Semin Immunopathol;39(2):137-152, 2017 Feb.
[Is] ISSN:1863-2300
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Dendritic cells (DCs) are specialized immune sentinels that play key role in maintaining immune homeostasis by efficiently regulating the delicate balance between protective immunity and tolerance to self. Although DCs respond to maturation signals present in the surrounding milieu, multiple layers of suppression also co-exist that reduce the infringement of tolerance against self-antigens. These tolerance inducing properties of DCs are governed by their origin and a range of other factors including distribution, cytokines, growth factors, and transcriptional programing, that collectively impart suppressive functions to these cells. DCs directing tolerance secrete anti-inflammatory cytokines and induce naïve T cells or B cells to differentiate into regulatory T cells (Tregs) or B cells. In this review, we provide a detailed outlook on the molecular mechanisms that induce functional specialization to govern central or peripheral tolerance. The tolerance-inducing nature of DCs can be exploited to overcome autoimmunity and rejection in graft transplantation.
[Mh] Termos MeSH primário: Células Dendríticas/imunologia
Células Dendríticas/metabolismo
Tolerância Imunológica
[Mh] Termos MeSH secundário: Animais
Apresentação do Antígeno/imunologia
Linfócitos B Reguladores/imunologia
Linfócitos B Reguladores/metabolismo
Diferenciação Celular
Apresentação Cruzada/imunologia
Citocinas/metabolismo
Células Dendríticas/classificação
Células Dendríticas/citologia
Regulação da Expressão Gênica
Fatores de Crescimento de Células Hematopoéticas/metabolismo
Células-Tronco Hematopoéticas/citologia
Células-Tronco Hematopoéticas/metabolismo
Homeostase
Seres Humanos
Imunomodulação
Peptídeos e Proteínas de Sinalização Intercelular/metabolismo
Proteínas de Membrana/metabolismo
Especificidade de Órgãos/imunologia
Subpopulações de Linfócitos T/imunologia
Subpopulações de Linfócitos T/metabolismo
Fatores de Transcrição/metabolismo
Transcrição Genética
Vacinas/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cytokines); 0 (Hematopoietic Cell Growth Factors); 0 (Intercellular Signaling Peptides and Proteins); 0 (Membrane Proteins); 0 (Transcription Factors); 0 (Vaccines); 0 (flt3 ligand protein)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161127
[St] Status:MEDLINE
[do] DOI:10.1007/s00281-016-0602-0


  2 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28005985
[Au] Autor:Langkilde A; Olsen LC; Sætrom P; Drabløs F; Besenbacher S; Raaby L; Johansen C; Iversen L
[Ad] Endereço:Department of Dermatology, Aarhus University Hospital, Aarhus C, Denmark.
[Ti] Título:Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-α.
[So] Source:PLoS One;11(12):e0167437, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Psoriasis is a chronic cutaneous inflammatory disease. The immunopathogenesis is a complex interplay between T cells, dendritic cells and the epidermis in which T cells and dendritic cells maintain skin inflammation. Anti-tumour necrosis factor (anti-TNF)-α agents have been approved for therapeutic use across a range of inflammatory disorders including psoriasis, but the anti-inflammatory mechanisms of anti-TNF-α in lesional psoriatic skin are not fully understood. We investigated early events in skin from psoriasis patients after treatment with anti-TNF-α antibodies by use of bioinformatics tools. We used the Human Gene 1.0 ST Array to analyse gene expression in punch biopsies taken from psoriatic patients before and also 4 and 14 days after initiation of treatment with the anti-TNF-α agent adalimumab. The gene expression was analysed by gene set enrichment analysis using the Functional Annotation Tool from DAVID Bioinformatics Resources. The most enriched pathway was visualised by the Pathview Package on Kyoto Encyclopedia of Genes and Genomes (KEGG) graphs. The analysis revealed new very early events in psoriasis after adalimumab treatment. Some of these events have been described after longer periods of anti-TNF-α treatment when clinical and histological changes appear, suggesting that effects of anti-TNF-α treatment on gene expression appear very early before clinical and histological changes. Combining microarray data on biopsies from psoriasis patients with pathway analysis allowed us to integrate in vitro findings into the identification of mechanisms that may be important in vivo. Furthermore, these results may reflect primary effect of anti-TNF-α treatment in contrast to studies of gene expression changes following clinical and histological changes, which may reflect secondary changes correlated to the healing of the skin.
[Mh] Termos MeSH primário: Adalimumab/uso terapêutico
Anti-Inflamatórios/uso terapêutico
Psoríase/tratamento farmacológico
Pele/metabolismo
Fator de Necrose Tumoral alfa/imunologia
[Mh] Termos MeSH secundário: Adalimumab/farmacologia
Adulto
Idoso
Anti-Inflamatórios/farmacologia
Citocinas/genética
Citocinas/metabolismo
Expressão Gênica/efeitos dos fármacos
Fatores de Crescimento de Células Hematopoéticas/genética
Fatores de Crescimento de Células Hematopoéticas/metabolismo
Seres Humanos
Meia-Idade
Análise de Sequência com Séries de Oligonucleotídeos
Fator de Crescimento Derivado de Plaquetas/genética
Fator de Crescimento Derivado de Plaquetas/metabolismo
Análise de Componente Principal
Psoríase/genética
Psoríase/patologia
Receptores de Citocinas/genética
Receptores de Citocinas/metabolismo
Pele/patologia
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Cytokines); 0 (Hematopoietic Cell Growth Factors); 0 (Platelet-Derived Growth Factor); 0 (Receptors, Cytokine); 0 (Tumor Necrosis Factor-alpha); FYS6T7F842 (Adalimumab)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170703
[Lr] Data última revisão:
170703
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161223
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0167437


  3 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27364565
[Au] Autor:Zhao B; Mei Y; Yang J; Ji P
[Ad] Endereço:Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
[Ti] Título:Erythropoietin-regulated oxidative stress negatively affects enucleation during terminal erythropoiesis.
[So] Source:Exp Hematol;44(10):975-81, 2016 Oct.
[Is] ISSN:1873-2399
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Differentiating erythroblasts are exposed to an oxidative environment. The dynamics of oxidative status during terminal erythropoiesis and how they affect cell differentiation in response to erythropoietin (Epo) are unclear. Here, we show that Epo induces reactive oxygen species (ROS) production in the early stages of terminal erythropoiesis. The levels of ROS correlate with CD71 surface expression and the uptake of iron and transferrin. ROS decreases in the late stages of terminal erythropoiesis, when the cells are preparing for enucleation. Consistently, treatment of erythroblasts with a low dose (5 mM) of N-acetyl-cysteine (NAC), a ROS scavenger, promotes enucleation. However, a high dose (20 mM) of NAC leads to significant cell death. Our study reveals an important function of Epo in regulating the dynamics of oxidative status and enucleation.
[Mh] Termos MeSH primário: Diferenciação Celular/efeitos dos fármacos
Eritroblastos/citologia
Eritroblastos/efeitos dos fármacos
Eritropoese/efeitos dos fármacos
Eritropoetina/farmacologia
[Mh] Termos MeSH secundário: Animais
Apoptose
Biomarcadores
Eritroblastos/metabolismo
Feto
Fatores de Crescimento de Células Hematopoéticas/farmacologia
Hemoglobinas/metabolismo
Imunofenotipagem
Ferro/metabolismo
Fígado/citologia
Camundongos
Estresse Oxidativo/efeitos dos fármacos
Espécies Reativas de Oxigênio/metabolismo
Transferrina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Hematopoietic Cell Growth Factors); 0 (Hemoglobins); 0 (Reactive Oxygen Species); 0 (Transferrin); 11096-26-7 (Erythropoietin); E1UOL152H7 (Iron)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171001
[Lr] Data última revisão:
171001
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160702
[St] Status:MEDLINE


  4 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27092550
[Au] Autor:Massolt ET; Effraimidis G; Korevaar TI; Wiersinga WM; Visser WE; Peeters RP; Drexhage HA
[Ad] Endereço:Division of Endocrinology, Department of Internal Medicine, Erasmus MC, 3000 CA, Rotterdam, The Netherlands.
[Ti] Título:Aberrant Levels of Hematopoietic/Neuronal Growth and Differentiation Factors in Euthyroid Women at Risk for Autoimmune Thyroid Disease.
[So] Source:PLoS One;11(4):e0153892, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Subjects at risk for major mood disorders have a higher risk to develop autoimmune thyroid disease (AITD) and vice-versa, implying a shared pathogenesis. In mood disorder patients, an abnormal profile of hematopoietic/neuronal growth factors is observed, suggesting that growth/differentiation abnormalities of these cell lineages may predispose to mood disorders. The first objective of our study was to investigate whether an aberrant profile of these hematopoietic/neuronal growth factors is also detectable in subjects at risk for AITD. A second objective was to study the inter relationship of these factors with previously determined and published growth factors/cytokines in the same subjects. METHODS: We studied 64 TPO-Ab-negative females with at least 1 first- or second-degree relative with AITD, 32 of whom did and 32 who did not seroconvert to TPO-Ab positivity in 5-year follow-up. Subjects were compared with 32 healthy controls (HCs). We measured serum levels of brain-derived neurotrophic factor (BDNF), Stem Cell Factor (SCF), Insulin-like Growth Factor-Binding Protein 2 (IGFBP-2), Epidermal Growth Factor (EGF) and IL-7 at baseline. RESULTS: BDNF was significantly lower (8.2 vs 18.9 ng/ml, P<0.001), while EGF (506.9 vs 307.6 pg/ml, P = 0.003) and IGFBP-2 (388.3 vs 188.5 ng/ml, P = 0.028) were significantly higher in relatives than in HCs. Relatives who seroconverted in the next 5 years had significantly higher levels of SCF than non-seroconverters (26.5 vs 16.7 pg/ml, P = 0.017). In a cluster analysis with the previously published growth factors/cytokines SCF clustered together with IL-1ß, IL-6 and CCL-3, of which high levels also preceded seroconversion. CONCLUSION: Relatives of AITD patients show aberrant serum levels of 4 hematopoietic/neuronal growth factors similar to the aberrancies found in mood disorder patients, suggesting that shared growth and differentiation defects in both the hematopoietic and neuronal system may underlie thyroid autoimmunity and mood disorders. A distinct pattern of four inter correlating immune factors in the relatives preceded TPO-Ab seroconversion in the next 5 years.
[Mh] Termos MeSH primário: Fator Neurotrófico Derivado do Encéfalo/sangue
Fatores de Diferenciação de Crescimento/sangue
Fatores de Crescimento de Células Hematopoéticas/sangue
Fatores de Crescimento Neural/sangue
Tireoidite Autoimune/sangue
[Mh] Termos MeSH secundário: Estudos de Casos e Controles
Feminino
Seguimentos
Seres Humanos
Proteína 2 de Ligação a Fator de Crescimento Semelhante à Insulina/sangue
Interleucina-1beta/sangue
Interleucina-6/sangue
Interleucina-7/sangue
Transtornos do Humor/sangue
Transtornos do Humor/metabolismo
Risco
Glândula Tireoide/metabolismo
Tireoidite Autoimune/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Brain-Derived Neurotrophic Factor); 0 (Growth Differentiation Factors); 0 (Hematopoietic Cell Growth Factors); 0 (Insulin-Like Growth Factor Binding Protein 2); 0 (Interleukin-1beta); 0 (Interleukin-6); 0 (Interleukin-7); 0 (Nerve Growth Factors)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160430
[Lr] Data última revisão:
160430
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160420
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0153892


  5 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27090409
[Au] Autor:Miller PH; Knapp DJ; Beer PA; MacAldaz M; Rabu G; Cheung AM; Wei L; Eaves CJ
[Ad] Endereço:Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada; Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
[Ti] Título:Early production of human neutrophils and platelets posttransplant is severely compromised by growth factor exposure.
[So] Source:Exp Hematol;44(7):635-40, 2016 Jul.
[Is] ISSN:1873-2399
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The critical human cells that produce neutrophils and platelets within 3 weeks in recipients of hematopoietic transplants are thought to produce these mature blood cells with the same kinetics in sublethally irradiated immunodeficient mice. Quantification of their numbers indicates their relative underrepresentation in cord blood (CB), likely explaining the clinical inadequacy of single CB units in rescuing hematopoiesis in myelosuppressed adult patients. We here describe that exposure of CD34(+) CB cells ex vivo to growth factors that markedly expand their numbers and colony-forming cell content also rapidly (within 24 hours) produce a significant and sustained net loss of their original short-term repopulating activity. This loss of short-term in vivo repopulating activity affects early platelet production faster than early neutrophil output, consistent with their origin from distinct input populations. Moreover, this growth factor-mediated loss is not abrogated by published strategies to increase progenitor homing despite evidence that the effect on rapid neutrophil production is paralleled in time and amount by a loss of the homing of their committed clonogenic precursors to the bone marrow. These results highlight the inability of in vitro or phenotype assessments to reliably predict clinical engraftment kinetics of cultured CB cells.
[Mh] Termos MeSH primário: Plaquetas/metabolismo
Peptídeos e Proteínas de Sinalização Intercelular/metabolismo
Mielopoese
Neutrófilos/metabolismo
Trombopoese
[Mh] Termos MeSH secundário: Animais
Diferenciação Celular/efeitos dos fármacos
Células Cultivadas
Sobrevivência de Enxerto
Fatores de Crescimento de Células Hematopoéticas/metabolismo
Fatores de Crescimento de Células Hematopoéticas/farmacologia
Transplante de Células-Tronco Hematopoéticas
Células-Tronco Hematopoéticas/citologia
Células-Tronco Hematopoéticas/efeitos dos fármacos
Células-Tronco Hematopoéticas/metabolismo
Seres Humanos
Peptídeos e Proteínas de Sinalização Intercelular/farmacologia
Camundongos
Mielopoese/efeitos dos fármacos
Trombopoese/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hematopoietic Cell Growth Factors); 0 (Intercellular Signaling Peptides and Proteins)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170530
[Lr] Data última revisão:
170530
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160420
[St] Status:MEDLINE


  6 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26787093
[Au] Autor:Yu JH; Seo JH; Lee JY; Lee MY; Cho SR
[Ad] Endereço:Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Korea.
[Ti] Título:Induction of Neurorestoration From Endogenous Stem Cells.
[So] Source:Cell Transplant;25(5):863-82, 2016.
[Is] ISSN:1555-3892
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Neural stem cells (NSCs) persist in the subventricular zone lining the ventricles of the adult brain. The resident stem/progenitor cells can be stimulated in vivo by neurotrophic factors, hematopoietic growth factors, magnetic stimulation, and/or physical exercise. In both animals and humans, the differentiation and survival of neurons arising from the subventricular zone may also be regulated by the trophic factors. Since stem/progenitor cells present in the adult brain and the production of new neurons occurs at specific sites, there is a possibility for the treatment of incurable neurological diseases. It might be feasible to induce neurogenesis, which would be particularly efficacious in the treatment of striatal neurodegenerative conditions such as Huntington's disease, as well as cerebrovascular diseases such as ischemic stroke and cerebral palsy, conditions that are widely seen in the clinics. Understanding of the molecular control of endogenous NSC activation and progenitor cell mobilization will likely provide many new opportunities as therapeutic strategies. In this review, we focus on endogenous stem/progenitor cell activation that occurs in response to exogenous factors including neurotrophic factors, hematopoietic growth factors, magnetic stimulation, and an enriched environment. Taken together, these findings suggest the possibility that functional brain repair through induced neurorestoration from endogenous stem cells may soon be a clinical reality.
[Mh] Termos MeSH primário: Terapia Baseada em Transplante de Células e Tecidos
Ventrículos Cerebrais/citologia
Transtornos Cerebrovasculares/terapia
Regeneração Nervosa/fisiologia
Células-Tronco Neurais/citologia
Doenças Neurodegenerativas/terapia
Neurogênese/fisiologia
[Mh] Termos MeSH secundário: Exercício
Fatores de Crescimento de Células Hematopoéticas/metabolismo
Seres Humanos
Fatores de Crescimento Neural/metabolismo
Estimulação Magnética Transcraniana
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Hematopoietic Cell Growth Factors); 0 (Nerve Growth Factors)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170315
[Lr] Data última revisão:
170315
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160121
[St] Status:MEDLINE
[do] DOI:10.3727/096368916X690511


  7 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26742020
[Au] Autor:Genova C; Rijavec E; Grossi F
[Ad] Endereço:IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
[Ti] Título:Hematopoietic growth factors in lung cancer.
[So] Source:Curr Opin Oncol;28(2):135-44, 2016 Mar.
[Is] ISSN:1531-703X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE OF REVIEW: Most patients affected by lung cancer are treated with chemotherapy, and hence are at risk of myelosuppression. Hematopoietic growth factors have a relevant role in this setting, as they can improve quality of life, reduce the rate of chemotherapy-induced complications and allow the administration of full-dose chemotherapy. RECENT FINDINGS: Most data of hematologic growth factors in lung cancer come from dated publications or large trials involving different malignancies, thus limiting specific information for lung neoplasms. Nonetheless, most studies consistently identified myeloid growth factors as effective on specific end-points such as the duration and severity of neutropenia, or complications such as hospitalizations and febrile neutropenia; on the other hand, erythropoiesis-stimulating agents (ESAs) consistently improved anemia-specific end-points including hemoglobin values, transfusions rate and fatigue, although some specific safety issues characterized this drug class. The most recent international guidelines address these characteristics and include the main indications for hematologic growth factors in solid neoplasms, including lung cancer. SUMMARY: Myeloid growth factors and ESAs have a relevant role in selected patients undergoing chemotherapy for nonsmall cell lung cancer and small cell lung cancer. Notably, a comprehensive risk-benefit assessment is required in the specific case of ESAs.
[Mh] Termos MeSH primário: Anemia/tratamento farmacológico
Neutropenia Febril Induzida por Quimioterapia/prevenção & controle
Hematínicos/uso terapêutico
Fármacos Hematológicos/uso terapêutico
Fatores de Crescimento de Células Hematopoéticas/uso terapêutico
Neoplasias Pulmonares/tratamento farmacológico
[Mh] Termos MeSH secundário: Anemia/induzido quimicamente
Anemia/prevenção & controle
Neutropenia Febril Induzida por Quimioterapia/tratamento farmacológico
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hematinics); 0 (Hematologic Agents); 0 (Hematopoietic Cell Growth Factors)
[Em] Mês de entrada:1611
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160108
[St] Status:MEDLINE
[do] DOI:10.1097/CCO.0000000000000268


  8 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26564003
[Au] Autor:Schiro A; Wilkinson FL; Weston R; Smyth JV; Serracino-Inglott F; Alexander MY
[Ad] Endereço:Regional Vascular and Endovascular Unit, Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK, M13 9WL.
[Ti] Título:Elevated levels of endothelial-derived microparticles, and serum CXCL9 and SCGF-ß are associated with unstable asymptomatic carotid plaques.
[So] Source:Sci Rep;5:16658, 2015 Nov 13.
[Is] ISSN:2045-2322
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Endothelial microparticles (EMPs) are released from dysfunctional endothelial cells. We hypothesised that patients with unstable carotid plaque have higher levels of circulating microparticles compared to patients with stable plaques, and may correlate with serum markers of plaque instability and inflammation. Circulating EMPs, platelet MPs (PMPs) and inflammatory markers were measured in healthy controls and patients undergoing carotid endarterectomy. EMP/PMPs were quantified using flow cytometry. Bioplex assays profiled systemic inflammatory and bone-related proteins. Immunohistological analysis detailed the contribution of differentially-regulated systemic markers to plaque pathology. Alizarin red staining showed calcification. EMPs and PMPs were significantly higher in patients with carotid stenosis (≥ 70%) compared to controls, with no differences between asymptomatic vs symptomatic patients. Asymptomatic patients with unstable plaques exhibited higher levels of EMPs, CXCL9 and SCGF-ß compared to those with stable plaques. CXCL9, and SCGF-ß were detected within all plaques, suggesting a contribution to both localised and systemic inflammation. Osteopontin and osteoprotegerin were significantly elevated in the symptomatic vs asymptomatic group, while osteocalcin was higher in asymptomatic patients with stable plaque. All plaques exhibited calcification, which was significantly greater in asymptomatic patients. This may impact on plaque stability. These data could be important in identifying patients at most benefit from intervention.
[Mh] Termos MeSH primário: Estenose das Carótidas/cirurgia
Micropartículas Derivadas de Células/metabolismo
Quimiocina CXCL9/sangue
Células Endoteliais/metabolismo
Fatores de Crescimento de Células Hematopoéticas/sangue
Lectinas Tipo C/sangue
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Estenose das Carótidas/sangue
Estenose das Carótidas/metabolismo
Citocinas/sangue
Endarterectomia das Carótidas
Feminino
Seres Humanos
Mediadores da Inflamação/sangue
Masculino
Meia-Idade
Osteocalcina/sangue
Osteopontina/sangue
Osteoprotegerina/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (CLEC11A protein, human); 0 (Chemokine CXCL9); 0 (Cytokines); 0 (Hematopoietic Cell Growth Factors); 0 (Inflammation Mediators); 0 (Lectins, C-Type); 0 (Osteoprotegerin); 104982-03-8 (Osteocalcin); 106441-73-0 (Osteopontin)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151114
[St] Status:MEDLINE
[do] DOI:10.1038/srep16658


  9 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26535734
[Au] Autor:Mu MW; Zhao ZY; Li CG
[Ad] Endereço:Department of Orthopedics, Dongzhimen Hospital Beijing University of Chinese Medicine, Beijing, China.
[Ti] Título:Comparative study of neural differentiation of bone marrow mesenchymal stem cells by different induction methods.
[So] Source:Genet Mol Res;14(4):14169-76, 2015 Oct 30.
[Is] ISSN:1676-5680
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Neurogenic differentiation of bone marrow (BM) mesenchymal stem cells (MSCs) offers a new hope for patients with many neurological disorders. Several chemical inducers are employed to induce BMMSCs differentiation into nerve cells. In the present study, we compared different inducers [2-mercaptoethanol (BME), tretinoin (ATRA), dimethyl sulfoxide/butylated hydroxyanisole (DMSO/BHA), and indomethacin/3-isobutyl-1-methylxanthine (indomethacin/IBMX)] on the neurogenic differentiation of BMMSCs and aimed to identify a more efficient and safer method. The MSCs were first identified by their ability to adhere to plastic and by the expression of positive (CD44, CD90, and CD105) and negative (CD34) markers assessed by flow cytometry. The efficiency of the neurogenic differentiation was determined by assessing the mRNA and protein expression of nestin, microtubule-associated protein-2 (MAP2), neuron specific enolase (NSE), and glial fibrillary acidic protein (GFAP) by reverse transcription-polymerase chain reaction and western-blot, respectively. The effect of these inducers on cell viability was also evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. This comprehensive study shows that indomethacin/IBMX is better than BME, DMSO/BHA, and ATRA both in terms of efficiency and safety, while BME suppressed the growth and proliferation of MSCs.
[Mh] Termos MeSH primário: Células da Medula Óssea/citologia
Técnicas Citológicas/métodos
Células Mesenquimais Estromais/citologia
Células-Tronco Neurais/citologia
Neurônios/citologia
[Mh] Termos MeSH secundário: Animais
Células da Medula Óssea/efeitos dos fármacos
Células da Medula Óssea/metabolismo
Hidroxianisol Butilado/farmacologia
Diferenciação Celular/efeitos dos fármacos
Diferenciação Celular/fisiologia
Sobrevivência Celular/efeitos dos fármacos
Células Cultivadas
Dimetil Sulfóxido/farmacologia
Fatores de Crescimento de Células Hematopoéticas/farmacologia
Indometacina/farmacologia
Masculino
Mercaptoetanol/farmacologia
Células Mesenquimais Estromais/efeitos dos fármacos
Células Mesenquimais Estromais/metabolismo
Células-Tronco Neurais/efeitos dos fármacos
Células-Tronco Neurais/metabolismo
Neurônios/efeitos dos fármacos
Ratos
Ratos Sprague-Dawley
Tretinoína/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hematopoietic Cell Growth Factors); 25013-16-5 (Butylated Hydroxyanisole); 5688UTC01R (Tretinoin); 60-24-2 (Mercaptoethanol); XXE1CET956 (Indomethacin); YOW8V9698H (Dimethyl Sulfoxide)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:151105
[Lr] Data última revisão:
151105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151105
[St] Status:MEDLINE
[do] DOI:10.4238/2015.October.29.39


  10 / 2325 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26440592
[Au] Autor:Weber KT; Satoh S; Alipui DO; Virojanapa J; Levine M; Sison C; Quraishi S; Bloom O; Chahine NO
[Ad] Endereço:The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY, 11030, USA.
[Ti] Título:Exploratory study for identifying systemic biomarkers that correlate with pain response in patients with intervertebral disc disorders.
[So] Source:Immunol Res;63(1-3):170-80, 2015 Dec.
[Is] ISSN:1559-0755
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Molecular events that drive disc damage and low back pain (LBP) may precede clinical manifestation of disease onset and can cause detrimental long-term effects such as disability. Biomarkers serve as objective molecular indicators of pathological processes. The goal of this study is to identify systemic biochemical factors as predictors of response to treatment of LBP with epidural steroid injection (ESI). Since inflammation plays a pivotal role in LBP, this pilot study investigates the effect of ESI on systemic levels of 48 inflammatory biochemical factors (cytokines, chemokines, and growth factors) and examines the relationship between biochemical factor levels and pain or disability in patients with disc herniation (DH), or other diagnoses (Other Dx) leading to low back pain, which included spinal stenosis (SS) and degenerative disc disease (DDD). Study participants (n = 16) were recruited from a back pain management practice. Pain numerical rating score (NRS), Oswestry Disability Index (ODI), and blood samples were collected pre- and at 7 to 10 days post-treatment. Blood samples were assayed for inflammatory mediators using commercial multiplex assays. Mediator levels were compared pre- and post-treatment to investigate the potential correlations between clinical and biochemical outcomes. Our results indicate that a single ESI significantly decreased systemic levels of SCGF-ß and IL-2. Improvement in pain in all subjects was correlated with changes in chemokines (MCP-1, MIG), hematopoietic progenitor factors (SCGF-ß), and factors that participate in angiogenesis/fibrosis (HGF), nociception (SCF, IFN-α2), and inflammation (IL-6, IL-10, IL-18, TRAIL). Levels of biochemical mediators varied based on diagnosis of LBP, and changes in pain responses and systemic mediators from pre- to post-treatment were dependent on the diagnosis cohort. In the DH cohort, levels of IL-17 and VEGF significantly decreased post-treatment. In the Other Dx cohort, levels of IL-2Rα, IL-3, and SCGF-ß significantly decreased post-treatment. In order to determine whether mediator changes were related to pain, correlations between change in pain scores and change in mediator levels were performed. Subjects with DH demonstrated a profile signature that implicated hematopoiesis factors (SCGF-ß, GM-CSF) in pain response, while subjects with Other Dx demonstrated a biomarker profile that implicated chemokines (MCP-1, MIG) and angiogenic factors (HGF, VEGF) in pain response. Our findings provide evidence that systemic biochemical factors in patients with LBP vary by diagnosis, and pain response to treatment is associated with a unique profile of biochemical responses in each diagnosis group. Future hypothesis-based studies with larger subject cohorts are warranted to confirm the findings of this pilot exploratory study.
[Mh] Termos MeSH primário: Biomarcadores/sangue
Citocinas/sangue
Fatores de Crescimento de Células Hematopoéticas/sangue
Mediadores da Inflamação/sangue
Disco Intervertebral/patologia
Lectinas Tipo C/sangue
Doenças Neurodegenerativas/diagnóstico
Dor/diagnóstico
Estenose Espinal/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Hematopoese
Seres Humanos
Injeções Epidurais
Masculino
Meia-Idade
Neovascularização Patológica
Doenças Neurodegenerativas/tratamento farmacológico
Dor/tratamento farmacológico
Estenose Espinal/tratamento farmacológico
Esteroides/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Biomarkers); 0 (CLEC11A protein, human); 0 (Cytokines); 0 (Hematopoietic Cell Growth Factors); 0 (Inflammation Mediators); 0 (Lectins, C-Type); 0 (Steroids)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151007
[St] Status:MEDLINE
[do] DOI:10.1007/s12026-015-8709-2



página 1 de 233 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde